This phase III trial is comparing the safety and effectiveness of a single drug treatment (belantamab mafodotin or blenrep) and a chemotherapy (pomalidomide plus low dose dexamethasone) for the treatment of patients with relapsed or refractory multiple myeloma.
This trial is treating patients with multiple myeloma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had a certain type of treatment or surgical procedure.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Low dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
Eligible patients will be randomised to receive belantamab mafodotin at a single agent dose of 2.5 mg/kg on Day 1 of each 3-week cycle OR oral pomalidomide at a starting dose of 4mg per day on Days 1 to 21 of each 28-day cycle and oral dexamethasone once weekly on Days 1, 8, 15 and 22.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More